SutroVax, Inc.









Spécialité Stade Position Conseil d’administration
Biotechnologie Pré-Clinique Co-investisseur Observateur
Dernière mise à jour: 11/07/2015




SutroVax, Inc. is a biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines. SutroVax is an independent company that was spun out of Sutro Biopharma with an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.  In addition to CTI Life Sciences Fund II, SutroVax is backed by leading investors including Abingworth, Longitude Capital, and Roche Venture Fund.


400 E Jamie Court, Suite 205

South San Francisco, CA 94080

Telephone: (650) 837-0111